Ningbo Linghan Enterprise Management Partnership Enterprise (Limited Partnership) entered into equity transaction contract to acquire 14.60% stake in Hangzhou Weisibo Medical Technology Co., Ltd. from Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) for CNY 8 million on December 29, 2022. As of October 26, 2022, Zhejiang Xianju Pharmaceutical directorate approved transfer of 14.60% stake in Hangzhou Weisibo Medical Technology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 CNY | +1.28% |
|
+3.76% | -7.05% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.05% | 1.62B | |
+55.11% | 811B | |
+43.82% | 640B | |
-6.42% | 353B | |
+19.36% | 333B | |
+9.75% | 302B | |
+17.31% | 246B | |
+2.49% | 225B | |
+12.81% | 218B | |
+9.06% | 168B |
- Stock Market
- Equities
- 002332 Stock
- News Zhejiang Xianju Pharmaceutical Co.,Ltd.
- Ningbo Linghan Enterprise Management Partnership Enterprise (Limited Partnership) entered into equity transaction contract to acquire 14.60% stake in Hangzhou Weisibo Medical Technology Co., Ltd. from Zhejiang Xianju Pharmaceutical Co.,Ltd. for CNY 8 million.